Comparative effectiveness of non-cisplatin first-line therapies for metastatic urothelial carcinoma: phase 2 IMvigor210 study versus US patients treated in the Veterans …

N Vander Velde, A Guerin, R Ionescu-Ittu, S Shi… - European Urology …, 2019 - Elsevier
Background First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …
被引用次数：22 相关文章
[PDF] stanford.edu

[PDF][PDF] Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in …

N Vander Velde, A Guerin, R Ionescu-Ittu… - EUROPEAN …, 2019 - med.stanford.edu
Background: First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …

Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the …

N Vander Velde, A Guerin… - European urology …, 2019 - pubmed.ncbi.nlm.nih.gov
Background First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …

Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the …

N Vander Velde, A Guerin… - European …, 2019 - euoncology.europeanurology.com
Background First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …

Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the …

N Vander Velde, A Guerin, R Ionescu-Ittu… - European Urology …, 2018 - europepmc.org
BACKGROUND: First-line treatments for cisplatin-ineligible patients with metastatic
urothelial carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint …
[PDF] stanford.edu

[PDF][PDF] Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in …

N Vander Velde, A Guerin, R Ionescu-Ittu… - EUROPEAN …, 2019 - wayback.stanford.edu
Background: First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …
[PDF] stanford.edu

[PDF][PDF] Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in …

N Vander Velde, A Guerin, R Ionescu-Ittu… - EUROPEAN …, 2019 - urology.stanford.edu
Background: First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …
[PDF] stanford.edu

[PDF][PDF] Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in …

N Vander Velde, A Guerin, R Ionescu-Ittu… - EUROPEAN …, 2019 - wayback.stanford.edu
Background: First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …